(Q44862770)

6 December 2017

title

Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients (English)

1 reference

6 December 2017

0 references

1 reference

T Nakamura

1

1 reference

6 December 2017

C Ushiyama

2

1 reference

6 December 2017

N Shimada

3

1 reference

6 December 2017

K Hayashi

4

1 reference

6 December 2017

I Ebihara

5

1 reference

6 December 2017

H Koide

6

1 reference

6 December 2017

language of work or name

1 reference

1 September 2000

1 reference

Journal of Diabetes and its Complications

6 December 2017

published in

1 reference

6 December 2017

volume

14

1 reference

6 December 2017

issue

5

1 reference

6 December 2017

page(s)

250-254

1 reference

Troglitazone and pioglitazone attenuate agonist-dependent Ca2+ mobilization and cell proliferation in vascular smooth muscle cells

6 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900124-0

7 January 2021

Acute and chronic effects of troglitazone (CS-045) on isolated rat ventricular cardiomyocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900124-0

7 January 2021

Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900124-0

7 January 2021

Endothelin-1 urinary excretion, but not endothelin-1 plasma concentration, is increased in renovascular hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900124-0

7 January 2021

Role of plasma and urinary endothelin-1 in early diabetic and hypertensive nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900124-0

7 January 2021

Increased plasma metalloproteinase-9 concentrations precede development of microalbuminuria in non-insulin-dependent diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900124-0

7 January 2021

Troglitazone (CS-045) ameliorates albuminuria in streptozotocin-induced diabetic rats

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900124-0

7 January 2021

Plasma endothelin-1 levels in non-insulin dependent diabetes mellitus patients with macrovascular disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900124-0

7 January 2021

Endothelin: emerging role in diabetic vascular complications

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900124-0

7 January 2021

Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900124-0

7 January 2021

Endothelins in the normal and diseased kidney

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900124-0

7 January 2021

Value of urinary endothelin-1 in patients with primary vesicoureteral reflux

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900124-0

7 January 2021

The link between hyperglycaemia and diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900124-0

7 January 2021

Increased urinary endothelin-1-like immunoreactivity excretion in NIDDM patients with albuminuria

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900124-0

7 January 2021

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900124-0

7 January 2021

Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900124-0

7 January 2021

Renal actions of endothelin: linking cellular signaling pathways to kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900124-0

7 January 2021

Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideas

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900124-0

7 January 2021

Elevated urinary excretion of endothelins in streptozotocin diabetic rats.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900124-0

7 January 2021

Inhibition of oxidation of low density lipoprotein by troglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900124-0

7 January 2021

Prevention of albuminuria by aminoguanidine or ramipril in streptozotocin-induced diabetic rats is associated with the normalization of glomerular protein kinase C

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900124-0

7 January 2021

Renoprotection in diabetes: genetic and non-genetic risk factors and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900124-0

7 January 2021

Pas de deux or more: the sulfonylurea receptor and K+ channels

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900124-0

7 January 2021

Inhibitory effect of troglitazone on diabetic neuropathy in streptozotocin-induced diabetic rats

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900124-0

7 January 2021

Decrease of renal endothelin 1 content and gene expression in diabetic rats with moderate hyperglycemia

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900124-0

7 January 2021

A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900124-0

7 January 2021

Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900124-0

7 January 2021

10.1016/S1056-8727(00)00124-0

Identifiers

DOI

1 reference

6 December 2017

1 reference